Cargando…

Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice

The rapid increase in knowledge in tumour biology and tumour pathogenesis of triple-negative breast cancer (TNBC) has resulted in new therapeutic approaches and new therapeutic concepts for treatment. For years, TNBC has been considered to be a difficult-to-treat tumour due to its generally aggressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schneeweiss, Andreas, Denkert, Carsten, Fasching, Peter A., Fremd, Carlo, Gluz, Oleg, Kolberg-Liedtke, Cornelia, Loibl, Sibylle, Lück, Hans-Joachim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2019
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570613/ https://www.ncbi.nlm.nih.gov/pubmed/31217629 http://dx.doi.org/10.1055/a-0887-0285

Ejemplares similares

Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC
por: Massa, Chiara, et al.
Publicado: (2020)

Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
por: Gluz, Oleg, et al.
Publicado: (2020)

Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
por: Untch, Michael, et al.
Publicado: (2021)

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
por: Kriegsmann, Mark, et al.
Publicado: (2014)

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
por: Stevic, Ines, et al.
Publicado: (2018)

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
por: Guo, Sanxing, et al.
Publicado: (2020)

Neural Functions Play Different Roles in Triple Negative Breast Cancer (TNBC) and non-TNBC
por: Tan, Renbo, et al.
Publicado: (2020)

MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2020)

Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy
por: Issa-Nummer, Yasmin, et al.
Publicado: (2014)

Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial
por: Jank, Paul, et al.
Publicado: (2021)

Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial
por: Witzel, Isabell, et al.
Publicado: (2019)

The fate of chemoresistance in triple negative breast cancer (TNBC)
por: O’Reilly, Elma A., et al.
Publicado: (2015)

Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials
por: von Waldenfels, Gabriel, et al.
Publicado: (2018)

AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2022)

The exploration of contrasting pathways in Triple Negative Breast Cancer (TNBC)
por: Narrandes, Shavira, et al.
Publicado: (2018)

Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice
por: Losurdo, Agnese, et al.
Publicado: (2020)

Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro
por: Choi, Hoon Sik, et al.
Publicado: (2021)

Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
por: Lee, Jieun
Publicado: (2023)

Defining triple‐negative breast cancer with neuroendocrine differentiation (TNBC‐NED)
por: Hacking, Sean M, et al.
Publicado: (2023)

Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy
por: Kim, Sanghwa, et al.
Publicado: (2016)

Interleukin-3-Receptor-α in Triple-Negative Breast Cancer (TNBC): An Additional Novel Biomarker of TNBC Aggressiveness and a Therapeutic Target
por: Koni, Malvina, et al.
Publicado: (2022)

AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
por: Friedrich, Michael, et al.
Publicado: (2021)

Treatment of Early Breast Cancer: The 18th St. Gallen International Breast Cancer Consensus Conference against the Background of Current German Treatment Recommendations
por: Untch, Michael, et al.
Publicado: (2023)

Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
por: Friedrich, Michael, et al.
Publicado: (2021)

Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling
por: Vishnubalaji, Radhakrishnan, et al.
Publicado: (2021)

Recurrent triple-negative breast cancer (TNBC) tissues contain a higher amount of phosphatidylcholine (32:1) than non-recurrent TNBC tissues
por: Hosokawa, Yuko, et al.
Publicado: (2017)

Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial
por: Kolberg-Liedtke, Cornelia, et al.
Publicado: (2022)

Towards an immunoscore for triple negative breast cancer (TNBC): lymphocytic infiltrate predicts outcome
por: Adams, Sylvia, et al.
Publicado: (2013)

Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
por: Chaudhuri, Aiswarya, et al.
Publicado: (2022)

Tissue Selection for PD-L1 Testing in Triple Negative Breast Cancer (TNBC)
por: Dobritoiu, Florin, et al.
Publicado: (2022)

Chemotherapy with ceramide in TNBC
por: Legembre, Patrick, et al.
Publicado: (2015)

GHRH-antagonists in TNBC
por: Engel, Jörg B.
Publicado: (2015)

Cripto-1 in TNBC
por: Castro, Nadia P, et al.
Publicado: (2015)

Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy
por: Huober, Jens, et al.
Publicado: (2023)

47982 Reversing the resistance to chemotherapy in White and Black patients with triple negative breast cancer (TNBC).
por: Gandhi, Shipra, et al.
Publicado: (2021)

Prognostic Capability of TNBC 3-Gene Score among Triple-Negative Breast Cancer Subtypes
por: Araujo, Jhajaira M., et al.
Publicado: (2022)

AGO Algorithms for the Treatment of Breast Cancer: Update 2021
por: Schneeweiss, Andreas, et al.
Publicado: (2021)

Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial
por: Rüger, Alexandra Maria, et al.
Publicado: (2020)

The Landscape of Targeted Therapies in TNBC
por: Vagia, Elena, et al.
Publicado: (2020)

Tailoring Immunotherapy Treatment of Synchronous Renal Cell Carcinoma (RCC) and Triple-Negative Breast Cancer (TNBC)
por: Sheng, Iris Y., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5i88v30oiom4tl2avrb7sr7kbn